- Home
- MYGN vs MLAB Comparison
MYGN vs MLAB Comparison
Compare MYGN & MLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- MLAB
- Stock Information
- Founded
- MYGN 1991
- MLAB 1982
- Country
- MYGN United States
- MLAB United States
- Employees
- MYGN N/A
- MLAB N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- MLAB Industrial Machinery/Components
- Sector
- MYGN Health Care
- MLAB Industrials
- Exchange
- MYGN Nasdaq
- MLAB Nasdaq
- Market Cap
- MYGN 744.7M
- MLAB 680.0M
- IPO Year
- MYGN 1995
- MLAB N/A
- Fundamental
- Price
- MYGN $7.29
- MLAB $114.52
- Analyst Decision
- MYGN Hold
- MLAB Hold
- Analyst Count
- MYGN 16
- MLAB 2
- Target Price
- MYGN $20.17
- MLAB $140.00
- AVG Volume (30 Days)
- MYGN 1.2M
- MLAB 57.0K
- Earning Date
- MYGN 05-06-2025
- MLAB 05-30-2025
- Dividend Yield
- MYGN N/A
- MLAB 0.55%
- EPS Growth
- MYGN N/A
- MLAB N/A
- EPS
- MYGN N/A
- MLAB N/A
- Revenue
- MYGN $837,600,000.00
- MLAB $237,747,000.00
- Revenue This Year
- MYGN $2.99
- MLAB $13.48
- Revenue Next Year
- MYGN $8.36
- MLAB $4.74
- P/E Ratio
- MYGN N/A
- MLAB N/A
- Revenue Growth
- MYGN 11.21
- MLAB 11.68
- 52 Week Low
- MYGN $7.35
- MLAB $83.68
- 52 Week High
- MYGN $29.30
- MLAB $155.12
- Technical
- Relative Strength Index (RSI)
- MYGN 25.95
- MLAB 46.39
- Support Level
- MYGN $7.69
- MLAB $108.32
- Resistance Level
- MYGN $8.27
- MLAB $117.85
- Average True Range (ATR)
- MYGN 0.56
- MLAB 8.01
- MACD
- MYGN 0.02
- MLAB 0.82
- Stochastic Oscillator
- MYGN 1.02
- MLAB 73.23
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About MLAB Mesa Laboratories Inc.
Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in 4 divisions: Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables. The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Calibration Solutions division develops, manufactures, sells, and services quality control products.